Company news

Agios Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agios Reports Fourth Quarter and Full Year 2019 Financial Results

February 12, 2020

Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020

February 10, 2020

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

January 29, 2020

Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones

January 11, 2020

Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

December 22, 2019

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

December 15, 2019

Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

December 8, 2019

Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

December 8, 2019

Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

December 7, 2019

Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

December 1, 2019

Agios Appoints Jonathan Biller as Chief Legal Officer

November 24, 2019

Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

November 21, 2019

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

November 12, 2019

Agios Announces Pricing of $256 Million Public Offering of Common Stock

November 6, 2019

Agios Announces Proposed Offering of Common Stock

November 5, 2019

Agios Reports Business Highlights and Third Quarter 2019 Financial Results

October 30, 2019

Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

October 26, 2019

Agios Announces New Commercial Leadership Structure

April 1, 2019

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.